Boehringer Ingelheim reports Phase III data showing survodutide achieved up to 16.6% weight loss and significant metabolic improvements in adults with obesity.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Boehringer Ingelheim has reported positive topline results from the Phase III SYNCHRONIZE-1 trial (NCT06066515) evaluating the investigational dual glucagon/GLP-1 receptor agonist survodutide in adults with obesity or overweight without type 2 diabetes.
In the 76-week, placebo-controlled study, survodutide met both co-primary endpoints, with participants achieving an average weight reduction of up to 16.6% compared with 3.2% in the placebo group (p<0.0001), and up to 85.1% of treated individuals achieving at least 5% weight loss versus 38.8% with placebo.
Body weight reduction was primarily driven by fat loss, with minimal impact on lean mass.
The trial also showed a statistically significant reduction in waist circumference, a marker of visceral fat and cardiometabolic risk. Survodutide combines GLP-1–mediated appetite suppression with glucagon-related metabolic effects, including potential reductions in liver fat and improved metabolic regulation.
The safety profile was consistent with the GLP-1 class, with mainly mild to moderate and transient gastrointestinal events occurring more frequently during dose escalation and no new safety concerns identified.
Carel le Roux, M.D., Ph.D., Global Coordinating Investigator of the trial stated that the data support survodutide as a clinically meaningful treatment option for obesity and highlight the need for therapies that address broader metabolic health beyond weight reduction.
Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim added that the findings strengthen confidence in the therapy’s potential to address obesity and related conditions, including liver disease, and noted its possible role as a first-in-class dual glucagon/GLP-1 agonist.
Survodutide remains investigational and has not yet been approved, with full data from the trial expected to be presented at the American Diabetes Association Scientific Sessions 2026. The SYNCHRONIZE-1 study is part of a broader Phase III program evaluating the therapy across obesity subpopulations, alongside ongoing trials in metabolic dysfunction-associated steatohepatitis.
Reference
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.